Telmisartan activates peroxisome proliferator-activated receptor-g (PPARg) in addition to serving as an angiotensin II type 1 receptor (AT 1 R) blocker. The PPARg activity of telmisartan on resistance arteries has remained largely unknown. The present study investigated the hypothesis that telmisartan inhibited vascular tension in mouse mesenteric resistance arteries, which was attributed to an increased nitric oxide (NO) production through the PPARgdependent augmentation of expression and activity of endothelial nitric oxide synthase (eNOS).
Introduction
The renin-angiotensin-aldosterone system plays a central role in the development of hypertension and diabetic vascular disease. Angiotensin II (Ang II) induces cellular oxidative stress by activating the Ang II type 1 receptor (AT 1 R) and NAD(P)H oxidase and subsequent production of superoxide anions in both endothelial and vascular smooth muscle cells. Elevated levels of reactive oxygen species (ROS) lower the bioavailability of nitric oxide (NO), thus contributing to endothelial dysfunction. 1 -3 Consequently, AT 1 R blockers (ARBs) such as losartan represent a major class of anti-hypertensive drugs which reduce ROS overproduction in the vascular wall through antagonizing the AT 1 R. Peroxisome proliferator-activated receptor-g (PPARg) is a ligand-activated nuclear transcription factor, 4, 5 which regulates adipogenesis and glucose metabolism. 6 PPARg is expressed in endothelial and vascular smooth muscle cells, 7 and has been shown to enhance insulin sensitivity and mediate anti-inflammatory responses. 8 Mutations of PPARg in humans contribute to the pathogenesis of insulin resistance, diabetes, and hypertension. 9 PPARg agonists thiazolidinediones, such as rosiglitazone, are therapeutic choices for type 2 diabetes acting by enhancing the insulin sensitivity in liver, muscle, and adipose cells and by modulating lipid metabolism. 10 Activation of PPARg in endothelial and smooth muscle cells can produce cardioprotective benefit that is independent of insulin sensitivity. 7 Rosiglitazone and pioglitazone have been reported to ameliorate endothelial dysfunction in diabetic mouse by reducing the NAD(P)H oxidase expression and ROS production, 11, 12 while accumulating clinical reports show that full PPARg agonists are associated with deleterious side effects, such as congestive heart failure, 13, 14 exacerbation of fluid retention, causing oedema and weight gain 15, 16 as well as bone fractures in women with type 2 diabetes.
14 Substantial evidence suggests that telmisartan, an ARB approved for the treatment of hypertension, is a partial PPARg agonist. 17, 18 Clinical studies show that telmisartan is well tolerated and does not cause oedema and weight gain. 19, 20 In addition, telmisartan may be clinically more effective than losartan in lowering blood pressure in hypertensive patients. 21 On the other hand, telmisartan can activate PPARg partly due to its highly lipophilic nature 22 and its ability to bind to the PPARg ligand-binding domain. 17 This unique nature of being a dual ARB/PPARg agonist makes telmisartan a more promising drug in treating cardiovascular diseases in a safer manner. However, it remains unknown how the PPARg property of telmisartan alters vascular reactivity. The present study examined the hypothesis that telmisartan could enhance the expression of endothelial nitric oxide synthase (eNOS) via a PPARg-dependent mechanism to reduce ligand-induced contractions in mouse mesenteric resistance arteries.
Methods

Animals
The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . This study was approved by the Experimental Animal Ethics Committee, the Chinese University of Hong Kong. Male C57BL/6J mice aged between 12 and 13 weeks and age-matched eNOS knockout (eNOS KO) mice were supplied by the Laboratory Animal Services Center, the Chinese University of Hong Kong. PPARg KO mice were provided by Dr Jun Yu, the Chinese University of Hong Kong. The animals were housed in a temperature-controlled room (22 + 18C) under a 12 h light/dark cycle and had free access to water and the standard chow diet.
Artery preparation
Mice were sacrificed by CO 2 inhalation. Second-order mesenteric arteries and aortae were dissected out and placed in a dissecting dish containing the ice-cold phosphate buffered saline (PBS) in which the adhering connective tissues were carefully removed. The arterial tissues were cut into 1.0 -1.3 mm rings for tissue culture. ) was added in addition to 10 mmol L 21 telmisartan in separate experiments. The plate was gently shaken to allow thorough mixing of drugs before arteries were transferred to the wells for a 24 h incubation at 378C.
Tissue culture of arteries
Isometric force measurement
Tension changes of the cultured mesenteric arteries and aortae were recorded as previously described. 23 
Western blotting
Western blotting was performed as described elsewhere. 24 Mouse aortae harvested upon a 24 h incubation protocol were snap-frozen in liquid nitrogen. The tissues were homogenized in ice-cold radio-immunoprecipitation assay lysis buffer containing a cocktail of protease inhibitors (leupetin, 1 mg mL
21
; aprotonin, 5 mg mL
; PMSF, 100 mg mL
; sodium orthovanadate, 1 mmol L 21 ; ethylene glycol tetraacetic acid, 1 mmol L
; EDTA, 1 mmol L 21 ; NaF, 1 mmol L
; and b-glycerolphosphate, 2 mg mL
). The lysates were incubated on ice for 30 min and then centrifuged at 20 000 g for 20 min. The supernatant was collected and analysed for protein concentration using the Lowry method (Bio-Rad, USA). For each sample, 25 mg of the total protein was electrophoresed under reducing conditions through a SDS -polyacrylamide gel. The resolved proteins were electroblotted on an immobilon-P polyvinylidene difluoride membrane (Millipore, USA) using wet transfer at 100 V for 70 min at 48C. The membranes were blocked with 1% bovine serum albumin in 0.5% Tween-20 phosphate buffered saline (PBST) for 60 min before an overnight incubation with either polyclonal rabbit anti-PPARg antibody (1:1000, Cell Signaling), polyclonal rabbit anti-eNOS antibody (1:500, BD Transduction Laboratories), or polyclonal rabbit anti-phosphorylated eNOS antibody (1:1000, Upstate) at 48C. The membranes were then probed with a horseradish peroxidase-conjugated swine anti-rabbit secondary antibody at a dilution of 1:3000 for 1 h at room temperature. The membranes were developed with an enhanced chemiluminescence detection system (ECL reagents; Amersham PharmaciaBiotech, Bucks, UK) and then exposed to X-ray films. The signal intensities were quantified using a gel documentation system (GBOX-CHEM1-HR16, SynGene) and normalized with the housekeeping protein glyceraldehyde 3-phosphate dehydrogenase.
Real-time measurement on NO production in endothelial cells
Human aortic endothelial cells (HAEC) were purchased from Cascade Biologics (Oregon, USA) and cultured in Medium 200 supplemented with Low Serum Growth Supplement (Cascade Biologics) until 80% confluence upon which they were plated on coverslips. Cells were incubated with telmisartan (10 mmol L
21
) for 24 h with or without 30 min pretreatment of GW9662 (300 nmol L
) and then imaged as described earlier. 25 Briefly, cells after 24 h incubation were rinsed in NPSS
MgCl 2 , 10 mmol L 21 glucose, and 5 mmol L 21 HEPES, pH 7.4) and incubated with 1 mmol
′ -difluorescein, Invitrogen) for 10 min at room temperature. The cells were then excited at 495 nm with emission wavelength of 515 nm using the Olympus Fluoview FV1000 laser scanning confocal system (Olympus America, Inc., Melville, NY, USA) mounted on an inverted IX81 Olympus microscope. Basal NO levels were determined from the initial reading and real-time changes in ACh (10 mmol L
)-stimulated NO production were recorded and presented as a ratio of fluorescence relative to the initial intensity (time ¼ 0 min, before ACh addition).
Chronic treatment with telmisartan
C57BL/6J mice were orally treated with either telmisartan (1 mg kg 21 day
21
) or water for 14 days, after which mesenteric arteries were dissected for isometric force measurement.
Chemicals
Actinomycin-D, ODQ and N G -nitro-L-arginine methyl ester (L-NAME) were purchased from Tocris (Avonmouth, UK). 9,11-Dideoxy11a,9a-epoxymethanoprostaglandin F 2a (U46619), Ach, and GW9662 were purchased from Sigma-Aldrich (St Louis, MO, USA). Rosiglitazone was purchased from GlaxoSmithKline and olmesartan from Pfizer. Losartan was purchased from Cayman Chemical (Ann Arbor, MI, USA). Telmisartan was purchased from Changzhou Yabang Pharmaceutical Co., Ltd, Jiangsu Province, China and irbesartan from Zhejiang Apeloa Jiayuan Pharmaceutical Co. Ltd, Zhejiang Province, China. ACh and L-NAME was prepared in distilled water, while other chemicals were dissolved in dimethyl sulphoxide (DMSO, Sigma).
Statistical analysis
Data are means + SEM of n experiments and analysed with Student's t-test or two-way ANOVA followed by Bonferroni posthoc tests when more than two groups were compared. pD 2 is the negative logarithm of the vasoconstrictor concentration needed to produce half of the maximal contraction as determined by non-linear regression curve fitting (Graphpad Prism Software, version 4.0). P , 0.05 was considered statistically significant.
Results
Telmisartan inhibits U46619-induced contractions
Telmisartan concentration-dependently inhibited U46619-induced contractions in the mesenteric arteries from C57BL/6J mice. Telmisartan at 10 mmol L 21 attenuated the contractions (pD 2 : 7.89 + 0.04 for control and 7.40 + 0.07 for telmisartan 10 mmol L 21 , P , 0.001, Figure 1A , Supplementary material online, Figure 1A and Table 1 ). In contrast, losartan, olmesartan, and irbesartan (all used at 10 mmol L 21 ) did not alter the U46619-induced contractions (Supplementary material online, Figure 2A ). Telmisartan also enhanced ACh-induced endothelium-dependent relaxations (Supplementary material online, Figure 3A ). Similar findings were also obtained in the mouse aortae, in which telmisartan, but not losartan, olmesartan, and irbesartan, inhibited contractions to U46619 (Supplementary material online, Figure 4A ). Telmsartan also potentiated the ACh-induced relaxations in the mouse aortae (Supplementary material online, Figure 4D ).
Inhibitory effect of telmisartan on contractions is mediated by NO
L-NAME (100 mmol L
21
) abolished the inhibitory effect of telmisartan (10 mmol L 21 ) on U46619-induced contractions ( Figure 1B , Supplementary material online, Figure 1B and Table 1 ). ODQ (5 mmol L
) also prevented telmisartan-induced effect (Supplementary material online, Figure 2B and Table 1 ). In addition to U46619, telmisartan also suppressed contractions induced by endothelin-1 and this effect was abrogated by L-NAME ( Figure 1C , Table 1 ). In control rings without telmisartan treatment, L-NAME and ODQ enhanced the contractions to U46619 and endothelin-1 ( Figure 1B and C ) .
L-NAME abolished the enhanced ACh-induced relaxations in the mesenteric arteries (Supplementary material online, Figure 3A ) and reversed the telmisartan-induced inhibition on U46619-induced contractions in the aortae (Supplementary material online, Figure 4B ). Mesenteric arteries from C57BL/6J mice orally treated with telmisartan exhibited smaller U46619-induced contractions compared with those from vehicle-treated control mice. L-NAME restored and even potentiated U46619-induced contractions (Supplementary material online, Figure 5 ).
Telmisartan up-regulates eNOS expression and phosphorylation
Twenty four hour incubation of telmisartan concentrationdependently up-regulated the eNOS expression ( Figure 2A) and its phosphorylation at Ser 1177 ( Figure 2B ). The positive role of eNOS was further verified by eNOS KO mice, in which eNOS protein was not expressed in aortae ( Figure 2C ). L-NAME did not enhance the contractions to U46619 and telmisartan (10 mmol L 21 ) failed to inhibit contractions in mesenteric arteries from the eNOS KO mice ( Figure 2D ). In addition, the inhibitory effect of telmisartan to contractions was prevented by an RNA synthesis inhibitor, actinomycin-D (10 mmol L 21 ) ( Figure 3A and Table 1 ).
Telmisartan elevates PPARg expression via PPARg activity
Telmisartan concentration-dependently increased the PPARg expression ( Figure 3B ). Telmisartan (10 mmol L 21 )-induced up-regulation of PPARg expression was prevented by a PPARg antagonist GW9662 (300 nmol L
21
). Likewise, rosiglitazone, a PPARg agonist, also increased the GW9662-sensitve PPARg expression ( Figure 3C ). In contrast, losartan (10 mmol L 21 ) did not affect the expression of PPARg ( Figure 3C ). Table 1 ). Likewise, rosiglitazone (1 mmol L
Telmisartan-induced eNOS expression and activation are PPARg-dependent
21
) attenuated U46619-induced contractions, and this attenuation was reversed by GW9662 (Supplementary material online, Figure 2C ) and prevented by actinomycin-D (Supplementary material online, Figure 2D ).
Telmisartan (10 mmol L
) and rosiglitazone (1 mmol L 21 )-induced increases in eNOS expression ( Figure 4C ) and phosphorylation ( Figure 4D ) were prevented by GW9662 (300 mmol L
). On the contrary, losartan did not increase eNOS expression and only caused a slight elevation in eNOS phosphorylation, which was insensitive to GW9662 (Figure 4C and D) .
PPARg was not expressed in the PPARg KO mice ( Figure 5A ). In the mesenteric arteries of PPARg KO mice, the inhibitory effects of telmisartan (10 mmol L 21 ) on U46619-induced contractions were diminished compared with those in C57BL/6J control mice ( Figure 5B ). Telmisartan did not augment eNOS expression ( Figure 5C ) and phosphorylation ( Figure 5D ) in the aortae of PPARg KO mice.
Telmisartan increases intracellular NO levels in cultured endothelial cells
HAEC treated with telmisartan for 24 h exhibited higher un-stimulated (i.e. basal) NO level, which was prevented by co-treatment of GW9662 or exposure to L-NAME ( Figure 6A , before ACh addition at 0 min, Figure 6B ). Addition of ACh to HAEC stimulated NO production. The increase in intracellular NO level was remarkably higher in the telmisartan-treated cells compared with that of the untreated control. Cells co-treated with GW9662 exhibited a rise of NO level similar to that of the control and acute L-NAME treatment inhibited NO production ( Figure 6A and C )-treated mesenteric arteries from eNOS KO mice. Data are from 3 to 6 experiments. *P , 0.05 and **P , 0.01 vs. control; ***P , 0.001 vs. WT.
Telmisartan induces and activates eNOS via PPARg
Discussion
The present study demonstrated for the first time that telmisartan attenuates receptor-dependent contractions in the mesenteric resistance arteries and aortae from C57BL/6J mice via the activation of PPARg and a subsequent increase in eNOS expression and activity. The concentration-dependent inhibition of telmisartan on U46619-induced contractions implies its therapeutic potential in reducing over-constrictions caused by TP receptor activation in vascular complications of hypertension and diabetes. 26, 27 Thiazolinediones, such as rosiglitazone, have been reported to ameliorate endothelial dysfunction by inhibiting ROS production and stimulating NO generation via a PPARg-mediated pathway. 11, 12 Full PPARg agonists, pioglitazone, and troglitazone, increase NO production by up-regulating eNOS expression and eNOS-Ser 1177 phosphorylation in a rabbit model of myocardial infarction, 28 bovine endothelial cells, 29 and human umbilical vein endothelial cells (HUVEC). 30 We therefore hypothesized that telmisartan, acting as a partial agonist of PPARg, could also augment eNOS expression and activity in a PPARg-dependent manner, thereby inhibiting vasoconstriction. The present study shows that telmisartan-induced inhibition on U46619-induced contractions was attributed to the increase in NO production via an augmentation of eNOS expression and activity, evidenced by the abolishment of such inhibition by L-NAME and ODQ, as well as by the absence of the inhibition in arteries from eNOS KO mouse. Indeed, the potentiation of U46619-or ET-1-induced contractions by acute treatment of L-NAME or ODQ already suggests that basal NO can suppress vasoconstriction, in which the role of NO is further exaggerated by telmisartan treatment. The in vitro studies were supported by chronic oral administration of telmisartan to C57BL/6J mice, from which mesenteric arteries exhibited less U46619-induced contractions, and were markedly potentiated by L-NAME, indicating a significant increase of basal NO after telmisartan treatment. Telmisartan also enhanced the NO-mediated endothelium-dependent relaxations in both mesenteric arteries and aortae resulting from the increase in ACh-stimulated NO production.
Telmisartan-induced inhibition of contractions was significantly attenuated by actinomycin-D, confirming that transcriptional event was involved. In the present study, telmisartan increased eNOS phosphorylation at Ser 1177 as revealed by Western blot analysis on the mouse aortae, which exhibited similar telmisartan-induced effects and thus acted as the surrogate for molecular studies in regards to the very limited protein amount from the second-order mouse mesenteric arteries. In fact, eNOS is not only regulated at its expression level, but also its activity modified by phosphorylation 31 and post-translational mechanisms including the interaction of eNOS with other regulatory proteins. 32, 33 Increased eNOS phosphorylation may result from an increased eNOS expression by telmisartan and the elevated expression of other eNOS-interacting proteins. Telmisartan was reported to improve endothelial function by augmenting the vascular level of tetrahydrobiopterin (BH 4 , an eNOS cofactor) in aortae of Dahl salt-sensitive rats. 34 In addition, telmisartan up-regulates a BH 4 -synthesizing enzyme GTP cyclohydrolase I, which reduces eNOS uncoupling in diabetic rats. 35 Polikandriotis et al. showed that rosiglitazone elevates endothelial NO production by increasing heat shock protein 90 (hsp90) in HUVEC. 30 while hsp90 was identified to strengthen eNOS activities by promoting eNOS-Ser 1177 phosphorylation. 36 These observations may explain part of mechanisms by which telmisartan increases the eNOS activity in vasculatures. The critical role of PPARg in the telmisartan-induced effects in the arteries is pinpointed by the following observations. First, the attenuated U46619-induced contractions and the enhanced ACh-induced relaxations in the telmisartan-treated arteries, augmentation of aortic eNOS expression and phosphorylation, and elevated basal and ACh-stimulated NO levels in HAEC were all reversed by GW9662 (300 nmol L 21 ), a PPARg antagonist applied at a much Telmisartan induces and activates eNOS via PPARg lower concentration in the present study to avoid its non-specific antagonism on PPARa or PPARd when used in high concentrations (10 mmol L 21 ) as shown in previous reports. 37, 38 Second, the inhibition of U46619-induced contractions by telmisartan was markedly reduced in the mesenteric arteries from PPARg KO mice. It is reported that interference with PPARg signalling decreases endothelium-dependent but not endothelium-independent vasodilatation in small cerebral arteries, 39 suggesting that PPARg is likely to act on the endothelium. We confirmed that the lack of inhibitory effect of telmisartan in the arteries of PPARg KO mice is due to the absence of PPARg and therefore the PPARg-dependent eNOS expression and phosphorylation were not up-regulated. Third, losartan and olmesartan, two classical ARBs, did not exhibit the telmisartan-like effects. Even irbesartan, an ARB that has been reported to slightly activate PPARg, failed to modify the U46619-induced contractions. Benson et al. 17 compared the PPARg activation capability of a variety of ARBs and found that telmisartan exhibits the strongest PPARg agonistic action (.20-fold activation), second by irbesartan which has only about two to three-fold slight activation, while none of the others (candesartan, valsartan, olmesartan, eprosartan, and EXP 3174, the active metabolite of losartan) can activate PPARg. Collectively, the unique PPARg-stimulating activity of telmisartan is essential in mediating the anti-contractile effects in the arteries, possibly independent of AT 1 R antagonism. The exceptional lipophilic nature of telmisartan allows it to behave as a PPARg agonist beyond its ARB activity. 22 In fact, telmisartan has the highest lipophilicity index (+3.20) whereas EXP 3174, an active metabolite of losartan, has the lowest (22.45) of the ARBs. 40 Telmisartan has a high volume of distribution compared with other ARBs as revealed by a test determining the ability of telmisartan to penetrate into tissues. 41 It is therefore thought that telmisartan possesses a greater capacity to penetrate cell membranes and thereby interacts with the nuclear PPARg. More importantly, molecular modelling reveals that telmisartan binds to helices H3, H6, and H7 of the key PPARg ligand-binding domain but other ARBs can only bind to helix H3. 17 Such difference may account for the substantially different potentials for activation of PPARg between telmisartan and other ARBs. Telmisartan increased PPARg expression as its full agonist rosiglitazone did, suggesting a novel positive feedback mechanism.
In conclusion, besides acting as an ARB, telmisartan uniquely and robustly activates PPARg. The present study demonstrates that telmisartan inhibits vasoconstriction through increased NO production arising from the elevated eNOS expression and phosphorylation at Ser 1177 via a PPARg-dependent mechanism. Compared with other ARBs, telmisartan, with the dual ARB/PPARg-agonistic properties, shall be a more promising drug with higher therapeutic value against vascular disorders associated with hypertension and type 2 diabetes.
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